Difference between revisions of "Part:BBa K4165058"

(Dry-lab Characterization)
(Dry-lab Characterization)
Line 18: Line 18:
  
 
===Dry-lab Characterization===
 
===Dry-lab Characterization===
 +
 
<html>
 
<html>
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/38-2.jpg" style="margin-left:300px;" alt="" width="400" /></p>
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/38-2.jpg" style="margin-left:300px;" alt="" width="400" /></p>
Line 25: Line 26:
  
  
This switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta. the pipeline for generating this model will be discussed in the next section in details
+
This switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta. the pipeline for generating this model will be discussed in the next section in details.
 
+
 
+
  
 
<h1>Switch construction Pipeline</h1>
 
<h1>Switch construction Pipeline</h1>
  
 
<html>
 
<html>
<p><img src="https://static.igem.wiki/teams/4165/wiki/registry/dry-lab-modelling-pipeline.png" style="margin-left:200px;" alt="" width="500" /></p>
+
<img src="https://static.igem.wiki/teams/4165/wiki/registry/dry-lab-modelling-pipeline.png" style="margin-left:200px;" alt="" width="500" /> <br>
 
</html>
 
</html>
  
  
                    Figure 2. A figure which dsecribes our Dry-Lab Modelling Pipeline. By team CU_Egypt 2022.
+
                  Figure 2. A figure which describes our Dry-Lab Modelling Pipeline. By team CU_Egypt 2022.
 
+
 
<html>
 
<html>
 
<p style=" font-weight: bold; font-size:14px;"> 1) Modelling </p>
 
<p style=" font-weight: bold; font-size:14px;"> 1) Modelling </p>
<p> Since our parts do not have experimentally acquired structures, we have to model them. This approach is done using both denovo modelling (ab initio) and template-based modelling. For modelling small peptides of our system, we used AppTest and Alphafold.</p>
+
<p> Since our Switch parts (HTRA1 binding peptide, TAU, and Beta-amyloid Binding peptide) do not have experimentally acquired structures, we modeled each one of them separately. This approach is done using both denovo modeling (ab initio) and template-based modeling. For modeling small peptides of our system, we used AppTest and Alphafold.</p>
 
<p style=" font-weight: bold; font-size:14px;"> 2) Structure Assessment </p>
 
<p style=" font-weight: bold; font-size:14px;"> 2) Structure Assessment </p>
<p>In order to assess the quality of our structures we used the Swiss-Model tool which gives an overall on quality of any 3D structure (For more information: <a href="https://2022.igem.wiki/cu-egypt/ProteinModelling.html"> Modelling</a>.</p>
+
<p>In order to assess the quality of generated structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our 
 +
<a href="https://2022.igem.wiki/cu-egypt/ProteinModelling.html">Modeling page</a>.</p>
 
<p style=" font-weight: bold; font-size:14px;"> 3) Quality Assessment </p>
 
<p style=" font-weight: bold; font-size:14px;"> 3) Quality Assessment </p>
 
+
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models out of score 6. For more information: <a href="https://2022.igem.wiki/cu-egypt/ProgrammingClub.html">Programming club page code under the name of Modric.</a>.</p>
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information: <a href="https://2022.igem.wiki/cu-egypt/software.html"> Software</a> under the name of Modric.</p>
+
  
 
<p style=" font-weight: bold; font-size:14px;">4) Filtering</p>
 
<p style=" font-weight: bold; font-size:14px;">4) Filtering</p>
<p>We take the top ranked models from the previous steps.</p>
+
<p>We take the top-ranked models from the previous steps that have either a score of 5 or 6 </p>
  
 
<p style=" font-weight: bold; font-size:14px;">5) Docking</p>
 
<p style=" font-weight: bold; font-size:14px;">5) Docking</p>
<p>The top models of inhibitor and HTRA Binding Peptide are docked with HtrA1 (BBa_K4165004).</p>
+
<p>The top models of inhibitor and HTRA Binding Peptide are docked with HtrA1, and the top models of the clamps are docked with the Target protein, that is, in our case is Beta-amyloid (BBa_K4165004).</p>
  
 
<p style=" font-weight: bold; font-size:14px;">6) Ranking</p>
 
<p style=" font-weight: bold; font-size:14px;">6) Ranking</p>
<p>The docking results are ranked according to their PRODIGY results. For more information: <a href="https://2022.igem.wiki/cu-egypt/Docking.html"> Docking</a>.</p>
+
<p>The docking results are ranked according to the Delta free energy generated by PRODIGY. For more information please check our <a href="https://2022.igem.wiki/cu-egypt/Docking.html">Docking page</a>.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">7) Top Models</p>
 
<p style=" font-weight: bold; font-size:14px;">7) Top Models</p>
<p>The results that came out from PRODIGY are ranked and top models are chosen to proceed with to the next step. For more information: <a href="https://2022.igem.wiki/cu-egypt/Docking.html"> Docking</a>.</p>
+
<p>The results from PRODIGY are ranked, and the top three models are chosen after the models are visualized to ensure that the proteins interact at the right designated domain to proceed with the next step. For more information please check our <a href="https://2022.igem.wiki/cu-egypt/Docking.html">Docking page</a>.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">8) Alignment</p>
 
<p style=" font-weight: bold; font-size:14px;">8) Alignment</p>
<p>Docked structures are aligned. This means that the HtrA1- binding peptide complex is aligned with the second complex which is the HtrA1-inhibitor complex to check whether they binded to the same site or not.</p>
+
<p>Docked structures are aligned. This means that the HtrA1- binding peptide complex is aligned with the second complex, the HtrA1-inhibitor complex, to check whether they bonded to the same site.</p>
<html>
+
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/picture10.png" style="margin-left:300px;" alt="" width="300" /></p>
+
 
 +
<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/picture10.png" style="margin-left:300px;" alt="" width="300" /></p>
 
</html>
 
</html>
  
  
                    Figure 3. Aligned structures of HtrA1 binding peptide 1 docked to HtrA1 and inhibitor docked to HtrA1.  
+
          Figure 3. Aligned structures of HtrA1 binding peptide 1 docked to HtrA1 and inhibitor docked to HtrA1.  
 +
<html>
 +
 
 
<p style=" font-weight: bold; font-size:14px;">9) Linker length</p>
 
<p style=" font-weight: bold; font-size:14px;">9) Linker length</p>
<p>The linker lengths are acquired by seeing the distance between the inhibitor and the HtrA1 binding peptide which is between both C terminals, N terminals, C- and N- terminal, and N- and C-terminals. The distance was measured to be between 13 and 25 angstrom</p>
+
<p>The linker lengths are acquired by seeing the distance between the inhibitor and the HtrA1 binding peptide between both C terminals, N terminals, C- and N- terminal, and N- and N- and C-terminals the linker length is calculated to be between 12.8 and 24.7 angstroms.</p>
 +
 
  
 
<p style=" font-weight: bold; font-size:14px;">10) Assembly</p>
 
<p style=" font-weight: bold; font-size:14px;">10) Assembly</p>
<p>After settling on the linkers lengths, now we will proceed to the assembly step of the whole system which is done using TRrosetta, AlphaFold, RosettaFold, and Modeller.</p>
+
<p>After settling on the linkers' lengths, we will now proceed to the assembly step of the whole system, which is done using TRrosetta, AlphaFold, RosettaFold, and Modeller.</p>
<html>
+
 
<p>a<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/ninhiibitor31-clamp.png" style="margin-left:50px;" alt="" width="150" />b<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/htra1-bp/h1b.jpg" style="margin-left:50px;" alt="" width="150" />c<img src="https://static.igem.wiki/teams/4165/wiki/q8iub5-trrosetta-model3.png" style="margin-left:50px;" alt="" width="150" /></p>
+
 
 +
<p>a<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/switch31/ninhiibitor31-clamp.png" style="margin-left:50px;" alt="" width="150"/> b<img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/htra1-bp/h1b.jpg" style="margin-left:50px;" alt="" width="150" />c<img src="https://static.igem.wiki/teams/4165/wiki/q8iub5-trrosetta-model3.png" style="margin-left:50px;" alt="" width="150" /></p>
 
</html>
 
</html>
  
    Figure 4. a) Seed_GGSGGGGG_seed clamp b) HTRA Binding Peptide 1 c)WAP-four disulfide core domain 13 serine protease inhibitor.
+
  Figure 4. a) Seed_GGSGGGGG_seed clamp b) HTRA Binding Peptide 1 c) WAP-four disulfide core domain 13 serine protease inhibitor.
 
<html>
 
<html>
 
<p style=" font-weight: bold; font-size:14px;">11) Structure Assessment</p>
 
<p style=" font-weight: bold; font-size:14px;">11) Structure Assessment</p>
<p>In order to assess the quality of our structures we used the Swiss-Model tool which gives an overall on quality of any 3D structure (For more information: <a href="https://2022.igem.wiki/cu-egypt/ProteinModelling.html"> Modeling</a>.</p>
+
<p>In order to assess the quality of our structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our <a href="https://2022.igem.wiki/cu-egypt/ProteinModelling.html">Modeling page</a>.</p>
  
 
<p style=" font-weight: bold; font-size:14px;">12) Quality Assessment </p>
 
<p style=" font-weight: bold; font-size:14px;">12) Quality Assessment </p>
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information: <a href="https://2022.igem.wiki/cu-egypt/software.html"> Software</a> under the name of Modric.</p>
+
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information, please proceed to our <a href="https://2022.igem.wiki/cu-egypt/ProgrammingClub.html">Programming club</a> under the name of Modric.</p>
 
+
 
+
<p style=" font-weight: bold; font-size:14px;">13) Ranking</p>
+
<p>Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information: <a href="https://2022.igem.wiki/cu-egypt/software.html"> Software</a> under the name of Abu Trika.</p>
+
 
<p style=" font-weight: bold; font-size:14px;">Table 1. quality assessment parameters of switch 39.</p>
 
<p style=" font-weight: bold; font-size:14px;">Table 1. quality assessment parameters of switch 39.</p>
 
<html>
 
<html>

Revision as of 01:29, 14 October 2022


HtrA1 Switch 38

This composite part consists of T7 promoter (BBa_K3633015), lac operator (BBa_K4165062), pGS-21a RBS (BBa_K4165016), 6x His-tag (BBa_K4165020), H1A (BBa_K4165000), GS Linker (BBa_K4165068), seed peptide (BBa_K4165012), GS Linker (BBa_K4165019), seed peptide (BBa_K4165012), GS Linker (BBa_K4165068), WAP inhibitor (BBa_K4165008), and T7 terminator (BBa_K731721).


Usage and Biology

Switch 38 is used to mediate the activity of HTRA1. It is composed of 3 parts connected by different linkers; an HtrA1 PDZ peptide, a clamp of two targeting peptides for tau or amyloid beta, and a catalytic domain inhibitor. Activating HTRA1 requires a conformational change in the linker, eliminating the attached inhibitor from the active site. The conformational rearrangement can be mediated through the binding of affinity clamp to tau or beta-amyloid. This binding will result in a tension that detaches the inhibitor from the active site.

The seed peptide which is considered as an amyloid binding peptide is proved experimentally to inhibit the aggregations of amyloid beta through cell viability assays with a survival rate values nearly 100%. The H1A peptide was also proven to bind with the PDZ of HtrA1 experimentally. The last part which is the inhibitor which is mainly a serine protease inhibitor, and since our protease is a serine protease, so it will act and inhibit the Protein. The whole construction was similarly proved from literature.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 502
    Illegal AgeI site found at 238
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry-lab Characterization

                                       Figure 1. The 3D structure of switch 38 modelled by tRrosseta.


This switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta. the pipeline for generating this model will be discussed in the next section in details.

Switch construction Pipeline



                 Figure 2. A figure which describes our Dry-Lab Modelling Pipeline. By team CU_Egypt 2022.

1) Modelling

Since our Switch parts (HTRA1 binding peptide, TAU, and Beta-amyloid Binding peptide) do not have experimentally acquired structures, we modeled each one of them separately. This approach is done using both denovo modeling (ab initio) and template-based modeling. For modeling small peptides of our system, we used AppTest and Alphafold.

2) Structure Assessment

In order to assess the quality of generated structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our Modeling page.

3) Quality Assessment

Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models out of score 6. For more information: Programming club page code under the name of Modric..

4) Filtering

We take the top-ranked models from the previous steps that have either a score of 5 or 6

5) Docking

The top models of inhibitor and HTRA Binding Peptide are docked with HtrA1, and the top models of the clamps are docked with the Target protein, that is, in our case is Beta-amyloid (BBa_K4165004).

6) Ranking

The docking results are ranked according to the Delta free energy generated by PRODIGY. For more information please check our Docking page.

7) Top Models

The results from PRODIGY are ranked, and the top three models are chosen after the models are visualized to ensure that the proteins interact at the right designated domain to proceed with the next step. For more information please check our Docking page.

8) Alignment

Docked structures are aligned. This means that the HtrA1- binding peptide complex is aligned with the second complex, the HtrA1-inhibitor complex, to check whether they bonded to the same site.


         Figure 3. Aligned structures of HtrA1 binding peptide 1 docked to HtrA1 and inhibitor docked to HtrA1. 

9) Linker length

The linker lengths are acquired by seeing the distance between the inhibitor and the HtrA1 binding peptide between both C terminals, N terminals, C- and N- terminal, and N- and N- and C-terminals the linker length is calculated to be between 12.8 and 24.7 angstroms.

10) Assembly

After settling on the linkers' lengths, we will now proceed to the assembly step of the whole system, which is done using TRrosetta, AlphaFold, RosettaFold, and Modeller.

a bc

  Figure 4. a) Seed_GGSGGGGG_seed clamp b) HTRA Binding Peptide 1 c) WAP-four disulfide core domain 13 serine protease inhibitor.

11) Structure Assessment

In order to assess the quality of our structures, we used the Swiss-Model tool, which gives an overall quality of any 3D structure (For more information, please check our Modeling page.

12) Quality Assessment

Using the code created by us (CU_Egypt 2022), we use the JSON files created from the structure assessment step in Swiss-Model to rank all the models For more information, please proceed to our Programming club under the name of Modric.

Table 1. quality assessment parameters of switch 39.

cbeta_deviations clashscore molprobity ramachandran_favored ramachandran_outliers Qmean_4 Qmean_6
0 154.75 2.65 98.44 0 -1.38724 -2.76799

Refernces

1. Lu, J., Cao, Q., Wang, C., Zheng, J., Luo, F., Xie, J., ... & Li, D. (2019). Structure-based peptide inhibitor design of amyloid-β aggregation. Frontiers in molecular neuroscience, 12, 54. 2. Romero-Molina, S., Ruiz-Blanco, Y. B., Mieres-Perez, J., Harms, M., Münch, J., Ehrmann, M., & Sanchez-Garcia, E. (2022). PPI-Affinity: A Web Tool for the Prediction and Optimization of Protein–Peptide and Protein–Protein Binding Affinity. Journal of Proteome Research. 3. Stein, V., & Alexandrov, K. (2014). Protease-based synthetic sensing and signal amplification. Proceedings of the National Academy of Sciences, 111(45), 15934-15939